Decapeptide-12

decapeptide-12, Lumixyl (Envy Medical trade name), oligopeptide-68 (a related but different Stanford peptide — do not confuse), YRSRKYSSWY

Skin & cosmetic

Awaiting medical reviewEN ES DE FR PT ZH+ Follow for updates

1What it is

Decapeptide-12 is a lab-designed peptide that came out of Stanford University dermatology research in the late 2000s. Researchers screened short peptides for the ability to block tyrosinase, the enzyme that starts melanin synthesis in pigment cells, and found that this ten-residue sequence blocked human tyrosinase in the test tube at concentrations far lower than hydroquinone, the standard prescription lightener (Abu Ubeid 2009, J Invest Dermatol). It was licensed and sold as Lumixyl from 2009 as a non-hydroquinone option for melasma and sun spots.

It is entirely synthetic and not a fragment of any natural protein. It is one of a small number of cosmetic peptides with any published, peer-reviewed human trial data for its specific claim.

2How it's thought to work

Tyrosinase converts tyrosine into the early intermediates of melanin inside melanocytes. Decapeptide-12 binds the enzyme reversibly and competitively, reducing its output.

Unlike hydroquinone, it is not reported to be toxic to melanocytes, which is the proposed reason it avoids the rebound and ochronosis (bluish-grey discolouration) concerns associated with long-term hydroquinone use.

In cultured human melanocytes it reduced melanin content by roughly a quarter to a third at low micromolar concentrations without reducing cell numbers.

Because it only slows new pigment, visible improvement depends on existing pigment being shed with normal turnover — hence 12–16 weeks in the studies, and the usual need for strict sun protection.

Proposed: a cosmetic decapeptide reported to inhibit tyrosinase, the committing enzyme of melanin synthesis, so the melanocyte packages and passes less pigment to the skin above it. Published evidence is small and largely from the manufacturer.Schematic — not to scale

3What the research shows

Melasma

A split-face, double-blind, randomised, placebo-controlled pilot in 5 women with recalcitrant melasma applied 0.01% decapeptide-12 cream to one side and vehicle to the other, twice daily for 16 weeks; the treated side improved on the MASI pigmentation score in all patients, with no significant change on the placebo side (Hantash & Jimenez 2009, J Drugs Dermatol). The design is strong but the number is tiny, so the grade is B. An open-label study in 10 Hispanic women with melasma reported around a 40% average MASI improvement after 16 weeks of 0.01% cream (Kassim 2012, J Clin Aesthet Dermatol). Uncontrolled. [2][3]

Graded B/—

Post-inflammatory hyperpigmentation and after procedures

Small open studies and case reports describe use after fractional laser or microneedling to reduce post-procedure pigmentation; small and uncontrolled, and procedure-dependent.

Tyrosinase inhibition in vitro

Inhibition of mushroom and human tyrosinase, reported as roughly 17-fold more potent than hydroquinone on a molar basis, with reduced melanin production in cultured melanocytes (Abu Ubeid 2009). [1]

Comparison with hydroquinone or tranexamic acid in people

No published head-to-head trial.

4Reported side effects and interactions

Literature-reported

Well tolerated in the small studies; no irritation, no depigmentation of normal skin and no ochronosis reported. Follow-up is short (16 weeks) and numbers are very small.

Community-reported

occasional mild dryness or stinging; frequent reports that the effect is gradual and modest, and that sun protection matters more than the serum.

Theoretical. any tyrosinase inhibitor could in principle lighten unaffected skin with heavy or prolonged use; not reported. Melasma returns with sun exposure regardless of the agent used.

Interactions. none pharmacological. Commonly layered with retinoids, azelaic acid, niacinamide, vitamin C and tranexamic acid; no documented problems, and no evidence on whether combinations add benefit.

Markers researchers commonly monitor

No blood markers are relevant to a topical pigment agent. Members tracking melasma or dark spots use: No compound-specific lab monitoring exists.

Marker	Why it's watched
Standardised photographs under identical, ideally cross-polarised or UV-flash lighting, every 4 weeks	pigment is subtle in ordinary light.
MASI or a simple self-score of area and darkness, the same way the trials measured it
Sun-exposure log	the biggest confounder; a bad fortnight in the sun undoes months of any lightener.

Free for everyone. Safety information is never behind a paywall.

5Reconstitution and handling

Topical only. Supplied in finished cosmeceutical products at 0.01%, or as raw peptide to formulators. Store products as labelled, away from heat and light; refrigerate raw peptide. There is no injectable form or rationale. The calculator does not apply.

Open in calculator, pre-loaded →

6Commonly studied alongside

GHK-Cu (#5) and Matrixyl (#111) in general anti-ageing routines; non-peptide pigment actives — tranexamic acid, azelaic acid, niacinamide, hydroquinone (as the standard it is compared against), retinoids; broad-spectrum sunscreen, which every melasma study treats as the foundation.

Informational cross-links. Not stack recommendations.

7Regulatory status by region

Region	Status (checked —)
United States	Permitted cosmetic ingredient; sold in physician-dispensed and over-the-counter cosmeceuticals. Not an FDA-approved drug; hydroquinone, by contrast, was removed from OTC status in 2020 and is prescription-only
European Union	Permitted cosmetic ingredient; listed in CosIng (hydroquinone is banned in EU cosmetics, which is part of the interest in alternatives)
United Kingdom	Same as EU
Australia	Cosmetic ingredient
South Africa	Cosmetic ingredient (hydroquinone is restricted in SA cosmetics)
Sport	Not listed by WADA

8Open questions

Adequately powered, independent randomised trials — the published has 5 patients.
Head-to-head comparison with hydroquinone, tranexamic acid or azelaic acid.
Long-term safety and whether benefit persists after stopping.
Whether it penetrates to melanocytes in the basal layer in meaningful amounts, or acts mainly on pigment transfer in the upper epidermis.

9References

1Abu Ubeid A et al. (2009). Short-sequence oligopeptides with inhibitory activity against mushroom and human tyrosinase. J Invest Dermatol. DOI
2Hantash BM, Jimenez F (2009). A split-face, double-blind, randomized and placebo-controlled pilot evaluation of a novel oligopeptide for the treatment of recalcitrant melasma. J Drugs Dermatol. PubMed
3Kassim AT et al. (2012). Open-label evaluation of the skin-brightening efficacy of a skin-brightening system using decapeptide-12. J Clin Aesthet Dermatol. PubMed
4Reddy BY, Jow T, Hantash BM (2012). Bioactive oligopeptides in dermatology: Part I. Exp Dermatol. PubMed · DOI
5Schagen SK (2017). Topical peptide treatments with effective anti-aging results. Cosmetics. DOI

References are being resolved to PubMed/DOI identifiers; links search PubMed for the citation until then.

10Community

forum threads →

community protocols include this →

Threads and protocols are visible to members. Joining is free.

Self-reported side effects Phase 2

Not enough data yet. 0 of the 50 members needed have logged this compound for 4+ weeks. We don't show anything below 50, so no one can be identified.

11Page history

26 Oct 2026Profile published — awaiting medical review

Licensed CC BY-NC-SA 4.0. Found an error? Report it · Editorial standards — corrections are logged here.